A Phase I/II Study of Bexarotene in Combination With ZD1839 (IRESSAÂ®) in the Treatment of Non-Small Cell Lung Cancer
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.
Lung Cancer
DRUG: Bexarotene|DRUG: Iressa
Overall response rate (RECIST CRITERIA), time to progression, toxicity, Completed 9/2005|Pharmacokinetic analysis, Completed 12/2005|Median survival, Calculated Spring 2008|Overall response rate (RECIST CRITERIA), time to progression, toxicity, Final analysis Spring 2008
The purpose of Phase 1 of this study is to evaluate the safety of the combination regimen, bexarotene and ZD1839. Phase II will evaluate the median survival, time to disease progression, and toxicity.